支付了之前的利息，自3月14日，新的利率调整到12%。and payment of accrued interest thereon, extending the maturity date to May 13, 2024. In connection with the extension, the interest rate was amended from 10% to 12% per annum, commencing on May 14, 2023.
“We are pleased that Hepalink has extended the debenture’s maturity date by an additional year, illustrating their continued support of our partnership,” stated Donald McCaffrey, President & CEO of Resverlogix. “The steadfast commitment of our partners allows us to focus on our mutual goal of advancing apabetalone’s clinical development, for the benefit of chronic disease patients. Over the past several months we have been working diligently with Hepalink in order to prepare for their involvement in our upcoming BETonMACE2 trial which has FDA Breakthrough Therapy Designation.”

同意再展期，部分反映出企业对208成药或Rvx其他机会的判断。

这个药的投入应该是打水漂了，不过对于海普瑞来说影响不大，权当买个经验

连600w也无法融资到，看来rvx已经剩下无几了！

公司近期仍致力于Apabetalong对Delta和Omicron引起的长新冠的影响研究，广谱且不受病毒变异影响的。

CALGARY, Alberta, March 02, 2023 - Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of two articles in peer-reviewed scientific journals. The first, entitled “Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation” by Fu et al., was published in International Immunopharmacology, and positions apabetalone as a variant-independent therapeutic for post COVID-19 conditions.
The article is published online HERE.
International Immunopharmacology Publication Highlights Include:
SARS-CoV-2, the virus responsible for COVID-19, binds human lung cells via interaction of the viral spike protein and the cell surface receptor called angiotensin converting enzyme 2 (ACE2)Apabetalone treatment reduces ACE2 to decrease binding of viral spike proteins including spike proteins from both the Delta and Omicron variantsApabetalone treatment also opposes the induction of COVID-related inflammatory mediators, in response to virus-mimicking stimulation of human lung cellsThis research highlights apabetalone’s potential to counter short- and long-term pathologic consequences of the SARS-CoV-2 virus, and positions it as a “variant-independent COVID therapeutic”
The second article, “Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells” by Wasiak et al., was published in Atherosclerosis, and provides new mechanistic insights in to apabetalone’s reduction of cardiovascular risk in obese patients.
The article is published online HERE.
Atherosclerosis Publication Highlights Include:
Apabetalone treatment was evaluated in a diet induced obesity (DIO) mouse modelMice on a high-fat diet had greater levels of vascular inflammation markers in the aorta, compared with those on a low-fat dietApabetalone treatment reduced the expression of pro-inflammatory genes in the high-fat diet fed mice compared to untreated controlsVascular inflammation is prevalent in obese patients and is a significant driver of negative cardiac eventsThis study helps us better understand the mechanism behind the observed cardioprotective benefits of apabetalone in the BETonMACE clinical trial
Finally, Resverlogix announced today its participation in the upcoming scientific conference hosted by the American College of Cardiology and the World Heart Federation (ACC.23/WCC) in New Orleans, LA. A poster, entitled “Epigenetic BET Reader Inhibitor Apabetalone / RVX-208 Counters Profibrotic and Contractile Activity of Cardiac Fibroblast with Potential Benefit for Heart Failure”, will be presented by Chief Scientific Officer, Dr. Ewelina Kulikowski, on Sunday March 5th, 2023.